Comparing Trinity Capital (NASDAQ:TRIN) and CERo Therapeutics (NASDAQ:CERO)

Trinity Capital (NASDAQ:TRIN) and CERo Therapeutics (NASDAQ:CERO) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Trinity Capital and CERo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trinity Capital	36.12%	16.73%	7.57%
CERo Therapeutics	N/A	N/A	N/A

Institutional & Insider Ownership

24.6% of Trinity Capital shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 6.4% of Trinity Capital shares are held by insiders. Comparatively, 15.8% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Trinity Capital and CERo Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Capital	$181.85 million	4.02	$76.89 million	$1.61	9.18
CERo Therapeutics	N/A	N/A	N/A	N/A	N/A

Trinity Capital has higher revenue and earnings than CERo Therapeutics.

Risk & Volatility

Trinity Capital has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Trinity Capital and CERo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Capital	0	1	5	0	2.83
CERo Therapeutics	0	0	0	0	N/A

Trinity Capital presently has a consensus target price of $15.50, indicating a potential upside of 4.87%. Given Trinity Capital’s higher probable upside, equities analysts clearly believe Trinity Capital is more favorable than CERo Therapeutics.

Summary

Trinity Capital beats CERo Therapeutics on 7 of the 9 factors compared between the two stocks.

About Trinity Capital

Trinity Capital Inc. is a business development company. It is a venture capital firm specializing in venture debt to growth stage companies looking for loans and/or equipment financing. Trinity Capital Inc. was founded in 2019 is based in Phoenix, Arizona with additional offices in the United States.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.